NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

ACAD

Acadia Pharmaceuticals Inc

May 20 • 04:00PM ET

21.69

Dollar change -0.30
Percentage change -1.36	%

Healthcare • Biotechnology • USA • NASD

Peers: NBIX BIIB VRTX INCY BMRN ALNY IONS REGN GILD AMGN

| Held by: IJR IWM VTI XBI FBT VB AVUV VXF VBK IWO

Scroll to Statements

Index	RUT	P/E	15.79	EPS (ttm)	1.37	Insider Own	0.78%	Shs Outstand	167.12M	Perf Week	26.10%
Market Cap	3.63B	Forward P/E	25.41	EPS next Y	0.85	Insider Trans	-1.88%	Shs Float	166.05M	Perf Month	50.83%
Income	228.88M	PEG	3.83	EPS next Q	0.14	Inst Own	103.76%	Short Float	9.19%	Perf Quarter	10.27%
Sales	996.28M	P/S	3.64	EPS this Y	-61.77%	Inst Trans	14.50%	Short Ratio	7.28	Perf Half Y	27.44%
Book/sh	4.58	P/B	4.74	EPS next Y	64.21%	ROA	23.03%	Short Interest	15.26M	Perf Year	46.06%
Cash/sh	4.07	P/C	5.33	EPS next 5Y	4.12%	ROE	37.24%	52W Range	13.40 - 25.23	Perf YTD	18.20%
Dividend Est.	-	P/FCF	24.45	EPS past 5Y	-	ROI	28.26%	52W High	-14.03%	Beta	0.69
Dividend TTM	-	Quick Ratio	2.80	Sales past 5Y	23.80%	Gross Margin	92.04%	52W Low	61.87%	ATR (14)	1.21
Dividend Ex-Date	-	Current Ratio	2.88	EPS Y/Y TTM	11860.68%	Oper. Margin	8.87%	RSI (14)	77.73	Volatility	10.85% 6.19%
Employees	654	Debt/Eq	0.07	Sales Y/Y TTM	22.42%	Profit Margin	22.97%	Recom	1.95	Target Price	25.89
Option/Short	Yes / Yes	LT Debt/Eq	0.06	EPS Q/Q	13.88%	Payout	0.00%	Rel Volume	1.39	Prev Close	21.99
Sales Surprise	2.32%	EPS Surprise	26.87%	Sales Q/Q	18.70%	Earnings	May 07 AMC	Avg Volume	2.10M	Price	21.69
SMA20	30.81%	SMA50	33.47%	SMA200	29.93%	Trades		Volume	2,923,173	Change	-1.36%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-11-25	Initiated	Deutsche Bank	Hold	$22
Jan-03-25	Downgrade	Guggenheim	Buy → Neutral	$23 → $20
Oct-10-24	Resumed	Raymond James	Mkt Perform
Aug-07-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$28 → $20
Jun-27-24	Initiated	BMO Capital Markets	Outperform	$31
Mar-12-24	Reiterated	Needham	Buy	$36 → $32
Mar-12-24	Downgrade	Mizuho	Buy → Neutral	$39 → $25
Jan-30-24	Initiated	Robert W. Baird	Outperform	$40
Jan-24-24	Upgrade	Needham	Hold → Buy	$37
Dec-19-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$31 → $40
Dec-14-23	Downgrade	Deutsche Bank	Buy → Hold	$25
Dec-13-23	Initiated	Citigroup	Buy	$38
Dec-12-23	Initiated	Deutsche Bank	Buy	$25
Nov-06-23	Upgrade	Mizuho	Neutral → Buy	$20 → $35
Oct-17-23	Initiated	UBS	Buy	$33
Oct-10-23	Upgrade	JP Morgan	Neutral → Overweight	$29 → $32
Jan-03-23	Upgrade	Guggenheim	Neutral → Buy	$22
Nov-04-22	Downgrade	Goldman	Neutral → Sell	$15 → $12
Nov-01-22	Initiated	Loop Capital	Hold	$17
Aug-08-22	Downgrade	Citigroup	Buy → Neutral	$19 → $15

Show Previous Ratings

Today 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
12:52PM	Why ACADIA Pharmaceuticals Inc. (ACAD) Skyrocketed on Friday (Insider Monkey)
10:55AM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
May-19-25 03:07PM	ACADIA Pharmaceuticals Stock Sees RS Rating Jump To 93 (Investor's Business Daily)
11:40AM	GSK or ACAD: Which Is the Better Value Stock Right Now? (Zacks)
09:32AM	Loading…
09:32AM	ACAD Stock Soars as US Court Rules in Favor of Key Nuplazid Patent (Zacks)
May-17-25 01:36PM	Acadia Pharmaceuticals price target raised to $19 from $17 at Oppenheimer (TipRanks)
01:36PM	Acadia Nuplazid patent ruling removes key overhang, says BMO Capital (TipRanks)
May-16-25 01:43PM	Delaware District Court Rules in Favor of Acadia in NUPLAZID (pimavanserin) Formulation Patent Litigation (Business Wire) +26.48%
May-09-25 06:26PM	Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates (Revised) (Zacks)
May-08-25 10:40AM	Acadia Q1 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth (Zacks) +14.31%
08:03AM	Q1 2025 ACADIA Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
03:28AM	ACADIA Pharmaceuticals Inc (ACAD) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
May-07-25 08:10PM	Acad projects $244.3M Q1 revenue with DAYBUE and NUPLAZID growth, anticipates accelerated Prader-Willi trial data (Seeking Alpha)
08:10PM	ACADIA Pharmaceuticals Inc. (ACAD) Q1 2025 Earnings Conference Call Transcript (Seeking Alpha)
05:35PM	Loading…
05:35PM	Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates (Zacks)
04:30PM	Acadia: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview (Business Wire)
10:00AM	Here are the major earnings after the close today (Seeking Alpha)
May-05-25 04:05PM	Acadia Pharmaceuticals to Participate in the BofA Securities 2025 Health Care Conference (Business Wire)
11:12AM	DENTSPLY SIRONA to Post Q1 Earnings: What's in Store for the Stock? (Zacks)
10:00AM	Analysts Estimate Fortrea Holdings Inc. (FTRE) to Report a Decline in Earnings: What to Look Out for (Zacks)
09:40AM	Why This 1 Value Stock Could Be a Great Addition to Your Portfolio (Zacks)
09:13AM	5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates (Zacks)
Apr-30-25 10:01AM	Earnings Preview: Acadia Pharmaceuticals (ACAD) Q1 Earnings Expected to Decline (Zacks)
Apr-23-25 04:05PM	Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025 (Business Wire)
Apr-15-25 10:20AM	Buy The Dips, Sell The Rips (Seeking Alpha)
Apr-11-25 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-10-25 02:37PM	'Carp Special': $100,000 In A 52-Week Low-Quality Portfolio (Seeking Alpha) -5.68%
09:31AM	Acadia (ACAD) Stock Jumps 6.1%: Will It Continue to Soar? (Zacks)
11:30AM	Loading…
Mar-28-25 11:30AM	Why Is Acadia (ACAD) Down 11.1% Since Last Earnings Report? (Zacks)
Mar-27-25 02:50PM	Soleno Therapeutics: In No Rush To Join Buying Frenzy Despite Vykat Approval (SeekingAlpha)
08:46AM	SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug (Zacks)
Mar-25-25 05:40PM	Is ACADIA Pharmaceuticals Inc. (ACAD) a Promising Biotech Stock According to Wall Street Analysts (InsiderMonkey)
Mar-21-25 09:20AM	Soleno Therapeutics: FDA Approval May Prove To Be A Pyrrhic Victory (SeekingAlpha)
Mar-17-25 03:39PM	Is ACADIA Pharmaceuticals Inc. (ACAD) the Best Nasdaq Stock Under $20 to Buy Now? (Insider Monkey)
Mar-14-25 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-13-25 04:05PM	Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences (Business Wire)
Mar-05-25 09:05AM	Clinical Data from Open-Label DAFFODIL Study Evaluating Long-term Safety of DAYBUE (trofinetide) in Patients with Rett Syndrome Published in Med (Business Wire)
06:36AM	Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates (Revised) (Zacks)
Mar-03-25 09:05AM	Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study (Business Wire) -7.35%
Feb-28-25 12:01PM	ACADIA Pharmaceuticals Inc (ACAD) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
Feb-27-25 04:05PM	Acadia Pharmaceuticals to Participate in the TD Cowens 45th Annual Health Care Conference (Business Wire)
12:01PM	ACADIA Pharmaceuticals Inc (ACAD) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic ... (GuruFocus.com)
Feb-26-25 05:25PM	Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates (Zacks)
04:35PM	Acadia: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview (Business Wire)
Feb-14-25 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-13-25 08:30AM	Is the Options Market Predicting a Spike in ACADIA Pharmaceuticals (ACAD) Stock? (Zacks)
Feb-12-25 04:05PM	Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025 (Business Wire)
Jan-17-25 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-14-25 01:10PM	Acadia Pharmaceuticals: Billion-Dollar Milestone and Global Expansion in 2025 (GuruFocus.com) -5.59%
09:05AM	Acadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
09:00AM	Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome (Business Wire)
Jan-12-25 09:33AM	Is ACADIA Pharmaceuticals (ACAD) the Best Medical Stock to Buy Under $20? (Insider Monkey)
Jan-02-25 02:58AM	Why ACADIA Pharmaceuticals Inc. (ACAD) Is Skyrocketing (Insider Monkey)
Dec-30-24 05:37PM	Acadia Pharmaceuticals Set to Join SandP SmallCap 600 (PR Newswire) +9.95%
05:37PM	Acadia Pharmaceuticals Set to Join S&P SmallCap 600 (PR Newswire)
Dec-19-24 04:05PM	Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025 (Business Wire)
Dec-16-24 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-11-24 04:05PM	Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million (Business Wire)
Dec-09-24 09:00AM	Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer (Business Wire) +8.56%
Dec-03-24 09:50AM	Why Acadia Pharmaceuticals (ACAD) is a Top Momentum Stock for the Long-Term (Zacks)
08:32AM	Implied Volatility Surging for ACADIA Pharmaceuticals (ACAD) Stock Options (Zacks)
Nov-27-24 07:06AM	Acadia signs agreement with Saniona to commercialise SAN711 (Pharmaceutical Technology)
Nov-26-24 04:05PM	Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711 (Business Wire)
Nov-21-24 04:05PM	Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences (Business Wire)
Nov-15-24 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-12-24 09:50AM	Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock (Zacks)
Nov-07-24 06:00AM	ACADIA Pharmaceuticals Inc (ACAD) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com) +8.93%
Nov-06-24 05:15PM	Acadia Pharmaceuticals (ACAD) Beats Q3 Earnings and Revenue Estimates (Zacks) +5.27%
04:13PM	Acadia: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview (Business Wire)
Nov-05-24 04:05PM	Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million (Business Wire)
Oct-31-24 02:22PM	ACADIA Pharmaceuticals Inc (ACAD): Worst-Performing Growth Stock in 2024 (Insider Monkey)
Oct-17-24 06:41PM	Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024 (Business Wire)
07:28AM	Health Canada approves Acadias DAYBUE for Rett syndrome (Pharmaceutical Technology)
Oct-16-24 04:07PM	Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE (trofinetide) for the Treatment of Rett Syndrome (Business Wire)
Oct-08-24 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-26-24 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-23-24 04:15PM	Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals (Business Wire)
Aug-29-24 08:30AM	Implied Volatility Surging for ACADIA Pharmaceuticals (ACAD) Stock Options (Zacks)
Aug-28-24 04:05PM	Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences (Business Wire)
Aug-14-24 08:04AM	Ryan Reynolds Announces More to Parkinsons Campaign (Business Wire)
Aug-07-24 04:30PM	Acadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth Conference (Business Wire) -19.52%
04:14PM	Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains' (Investor's Business Daily)
08:16AM	Acadia (ACAD) Q2 Earnings Beat, Product Sales Drive Revenues (Zacks)
Aug-06-24 05:45PM	Acadia Pharmaceuticals (ACAD) Beats Q2 Earnings and Revenue Estimates (Zacks)
04:42PM	Acadia: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview (Business Wire)
Jul-30-24 10:01AM	Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Jul-24-24 04:05PM	Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024 (Business Wire)
Jul-18-24 09:04AM	Clinical Data from Open-Label Extension LILAC-1 and LILAC-2 Studies Evaluating Long-Term Safety and Efficacy of DAYBUE (trofinetide) in Patients with Rett Syndrome Published in Med (Business Wire)
Jul-16-24 10:28AM	Acadia's (ACAD) Nuplazid Drives Growth, Pipeline Setbacks a Woe (Zacks)
Jun-21-24 12:24PM	Why Is ACADIA Pharmaceuticals Inc (ACAD) One of the Best Debt Free Halal Stocks According to Hedge Funds? (Insider Monkey)
10:53AM	7 Best Halal Stocks To Buy Now (Debt Free) (Insider Monkey)
Jun-18-24 09:04AM	Acadia Pharmaceuticals Presents DAYBUE (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting (Business Wire)
Jun-07-24 11:30AM	Acadia (ACAD) Up 0.6% Since Last Earnings Report: Can It Continue? (Zacks)
May-29-24 10:01AM	3 Sorry Pharma Stocks to Sell in May While You Still Can (InvestorPlace)
May-17-24 04:05PM	Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kihara James	PRINCIPAL ACCOUNTING OFFICER	May 16 '25	Sale	22.50	4,000	90,000	20,395	May 19 08:52 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	May 16 '25	Sale	25.00	2,000	50,000	62,130	May 19 08:50 PM
Schneyer Mark C.	Officer	May 16 '25	Proposed Sale	17.60	2,000	35,200		May 16 05:10 PM
Kihara James	Officer	May 16 '25	Proposed Sale	17.60	4,000	70,400		May 16 05:06 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	May 02 '25	Sale	14.60	1,327	19,374	23,526	May 02 08:00 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	May 02 '25	Sale	14.60	3,498	51,071	62,773	May 02 07:59 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Apr 08 '25	Sale	14.82	2,708	40,133	59,456	Apr 08 07:40 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	Apr 08 '25	Sale	14.82	1,028	15,235	22,257	Apr 08 07:38 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	Mar 26 '25	Sale	17.05	1,095	18,670	21,275	Mar 26 08:10 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Mar 26 '25	Sale	17.05	3,171	54,066	56,889	Mar 26 08:06 PM
GAROFALO ELIZABETH A.	Director	Mar 05 '25	Sale	18.23	4,919	89,673	17,595	Mar 06 06:30 PM
GAROFALO ELIZABETH A.	Director	Mar 05 '25	Proposed Sale	18.23	4,919	89,673		Mar 06 12:17 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	Feb 24 '25	Sale	19.96	475	9,481	20,228	Feb 25 06:48 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Feb 24 '25	Sale	19.96	773	15,429	53,882	Feb 25 06:46 PM
Teehan Brendan	EVP, COO, HEAD OF COMMERCIAL	Nov 19 '24	Sale	16.81	10,329	173,630	62,105	Nov 19 08:43 PM
Kihara James	PRINCIPAL ACCOUNTING OFFICER	Nov 19 '24	Sale	16.81	4,073	68,467	19,863	Nov 19 08:41 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Nov 19 '24	Sale	16.81	10,259	172,454	53,302	Nov 19 08:40 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Aug 19 '24	Sale	15.28	9,733	148,720	43,735	Aug 20 06:46 PM
Teehan Brendan	EVP, COO, HEAD OF COMMERCIAL	Aug 19 '24	Sale	15.28	9,534	145,680	52,177	Aug 20 06:43 PM
DAVIS STEPHEN	CEO	Aug 19 '24	Sale	15.28	31,747	485,094	186,555	Aug 20 06:40 PM
Schneyer Mark C.	EVP, CHIEF FINANCIAL OFFICER	Jun 10 '24	Sale	14.79	975	14,420	34,564	Jun 11 06:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ACAD

Acadia Pharmaceuticals Inc

Upgrade your FINVIZ experience